In Brief: Schering-Plough's Claritin
Executive Summary
Schering-Plough's Claritin: Loratadine syrup (10 mg per 10 mL, NDA 20-641) is approved by FDA Oct. 14 for use in patients six years of age and older. Schering touts Claritin as "the first and only nondrowsy antihistamine syrup for children"; Pfizer's antihistamine Zyrtec (cetirizine) was approved in a syrup formulation for children age six and older Sept. 27 ("The Pink Sheet" Oct. 7, In Brief). The children's dosage for Claritin is 10 mg syrup (two teaspoonsful) once daily, labeling states. The approved indication for Claritin 10 mg tablets has also been expanded to children age six and older...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth